Ascendis Pharma A/S (FRA:A71)
Germany · Delayed Price · Currency is EUR | Market Cap | 10.71B |
| Revenue (ttm) | 646.55M |
| Net Income (ttm) | -232.94M |
| Shares Out | n/a |
| EPS (ttm) | -3.87 |
| PE Ratio | n/a |
| Forward PE | 67.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 87 |
| Average Volume | 17 |
| Open | 179.00 |
| Previous Close | 177.00 |
| Day's Range | 179.00 - 180.00 |
| 52-Week Range | 115.00 - 190.00 |
| Beta | n/a |
| RSI | 52.50 |
| Earnings Date | Feb 11, 2026 |
About Ascendis Pharma
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses o... [Read more]
Financial Performance
In 2024, Ascendis Pharma's revenue was 363.64 million, an increase of 36.34% compared to the previous year's 266.72 million. Losses were -378.08 million, -21.47% less than in 2023.
Financial StatementsNews
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
Ascendis Pharma (NASDAQ: ASND) has outperformed the market over the past 10 years by 16.0% on an annualized basis producing an average annual return of 28.84%. Currently, Ascendis Pharma has a market...
Here's My Prediction For Who Could Acquire Ascendis Pharma
Ascendis Pharma (ASND) Shares Surge Amid Takeover Speculation
Ascendis Pharma (ASND) Shares Surge Amid Takeover Speculation
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
Ascendis Pharma (NASDAQ: ASND) has outperformed the market over the past 10 years by 16.13% on an annualized basis producing an average annual return of 28.9%. Currently, Ascendis Pharma has a market...
Ascendis Pharma (ASND) Faces Acquisition Rumor
Ascendis Pharma (ASND) Faces Acquisition Rumor
Ascendis Pharma gains amid takeover speculation
Looking Into Ascendis Pharma AS's Recent Short Interest
Ascendis Pharma AS's (NYSE: ASND) short interest as a percent of float has risen 10.27% since its last report. According to exchange reported data, there are now 3.30 million shares sold short , whic...
March 2026 Options Now Available For Ascendis Pharma (ASND)
Investors in Ascendis Pharma A/S (Symbol: ASND) saw new options begin trading today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pa...
Eight stock picks to play one of the healthiest corners of the market
The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull mar...
Stifel Raises Price Target for Ascendis Pharma (ASND) to $256 | ASND Stock News
Stifel Raises Price Target for Ascendis Pharma (ASND) to $256 | ASND Stock News
High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth
The Touchstone Mid Cap Growth Fund outperformed its benchmark, the Russell Midcap® Growth Index, for the quarter ended September 30, 2025. From a factor perspective, the Fund's overweight exposure to ...
Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades'
On CNBC's “ Halftime Report Final Trades ,” on Monday, Amy Raskin , chief investment officer at Chevy Chase Trust, named Ascendis Pharma A/S (NASDAQ: ASND) as her final trade . According to recent ne...
Final Trades: Ascendis Pharma, Monolithic Power, the IYC and the GPIQ
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Ascendis Pharma, Monolithic Power, the IYC and the GPIQ
The Investment Committee give you their top stocks to watch for the second half.
Trade Tracker: Amy Raskin shares her latest portfolio moves
Amy Raskin, chief investment officer at Chevy Chase Trust, joins CNBC's 'Halftime Report' to explain why she bought Ascendis Pharma and is buying more Cognex, SLB, Fanuc, AIA, CrowdStrike and Impinj.
Ascendis: Q3 Results Validate The TransCon Platform
Ascendis Pharma has achieved operational profitability, driven by YORVIPATH's rapid adoption and strong Q3 2025 revenues of €213.6 million. ASND's robust cash position (€539 million) and self-sustaini...
FDA Extends Review for Ascendis Pharma's (ASND) TransCon CNP
FDA Extends Review for Ascendis Pharma's (ASND) TransCon CNP
Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026
The U.S. Food & Drug Administration (FDA) on Tuesday extended review for Ascendis Pharma A/S ‘ (NASDAQ: ASND) New Drug Application (NDA) for TransCon CNP (navepegritide) for children with achondropla...
Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026
The U.S. Food & Drug Administration (FDA) on Tuesday extended review for Ascendis Pharma A/S‘ (NASDAQ: ASND) New Drug Application (NDA) for TransCon CNP (navepegritide) for children with achondroplasi...
Is the Market Bullish or Bearish on Ascendis Pharma AS?
Ascendis Pharma AS's (NYSE: ASND) short interest as a percent of float has risen 3.68% since its last report. According to exchange reported data, there are now 3.55 million shares sold short , which...
FDA Extends Decision Date For TransCon CNP In Pediatric Achondroplasia
(RTTNews) - Ascendis Pharma A/S (ASND), on Wednesday, reported that the FDA has extended the decision date for TransCon CNP, proposed for the treatment of children with achondroplasia, by three months...
Ascendis Pharma (ASND) Faces FDA Review Extension for TransCon CNP
Ascendis Pharma (ASND) Faces FDA Review Extension for TransCon CNP
US FDA extends review of Ascendis Pharma's therapy for children with dwarfism
The U.S. Food and Drug Administration on Tuesday extended its review of Ascendis Pharma's therapy for children with a rare genetic disorder that causes dwarfism, the company said.
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announ...
Ascendis Pharma (ASND): Wedbush Reiterates Outperform Rating | ASND Stock News
Ascendis Pharma (ASND): Wedbush Reiterates Outperform Rating | ASND Stock News